Dopaminergic influence of antipsychotic treatment outcomes in schizophrenia

Purpose: Schizophrenia is a challenging health condition characterized by a wide range of symptoms and varying responses to treatment. Studies on how genes affect drug responses have been promising. In particular, genes involved in the dopamine system of the brain, such as dopamine receptor D1 (<i>DRD1</i>), dopamine receptor D2 (<i>DRD2</i>), dopamine receptor D3 (<i>DRD3</i>), and catechol-O-methyltransferase (<i>COMT</i>) appear to play key roles in the response of patients to antipsychotic medications. This review examined studies on specific genes involved in the dopaminergic system, which plays a key role in how antipsychotic drugs work.Methods: The PubMed, Scopus, Web of Science, and Google Scholar databases were searched, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the protocol was registered with PROSPERO (CRD420251168294). Eligible studies included patients diagnosed with schizophrenia who were treated with antipsychotics and had dopaminergic gene variant data.Results: Of 73 screened articles, 26 met the inclusion criteria. Among the gene variants studied, <i>COMT</i> rs4680 and <i>DRD2</i> rs1800497 showed consistent links to treatment responses, particularly in reducing symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores. The relationship between genetic variants and clinical outcomes was statistically significant (P=0.007), whereas the study design showed no such association (P=0.416). Forest plots revealed varied effect sizes across gene families, with <i>COMT</i> and <i>DRD2</i> generally showing odds ratios >1.0, indicating a favorable impact on treatment.Conclusion: Our findings suggest that certain dopaminergic gene variants, especially <i>COMT</i> rs4680 and <i>DRD2</i> rs1800497, may serve as valuable markers for predicting the response of patients with schizophrenia to antipsychotic therapy.

Authors

Publication Details

Journal
Precision and Future Medicine
Published
2025-12-31
DOI
https://doi.org/10.23838/pfm.2025.00296
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dopaminergic influence of antipsychotic treatment outcomes in schizophrenia

Reem Ali Alhussain, Fai Sultan F. Almutairi, Sobhia N Abanmi, Zakiyah A. Aljeshi et al.
Precision and Future Medicine
Schizophrenia research and treatment
article

Dopaminergic influence of antipsychotic treatment outcomes in schizophrenia

Reem Ali Alhussain, Fai Sultan F. Almutairi, Sobhia N Abanmi, Zakiyah A. Aljeshi, Leen Alhodathi, Mazhar Mushtaq, Aasiyah Fagbo, Haneen Kadi, Abdulrahman Abdullah Altuwaim, Mashal Wahid, Hamna Saad
article en

Abstract

Purpose: Schizophrenia is a challenging health condition characterized by a wide range of symptoms and varying responses to treatment. Studies on how genes affect drug responses have been promising. In particular, genes involved in the dopamine system of the brain, such as dopamine receptor D1 (<i>DRD1</i>), dopamine receptor D2 (<i>DRD2</i>), dopamine receptor D3 (<i>DRD3</i>), and catechol-O-methyltransferase (<i>COMT</i>) appear to play key roles in the response of patients to antipsychotic medications. This review examined studies on specific genes involved in the dopaminergic system, which plays a key role in how antipsychotic drugs work.Methods: The PubMed, Scopus, Web of Science, and Google Scholar databases were searched, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the protocol was registered with PROSPERO (CRD420251168294). Eligible studies included patients diagnosed with schizophrenia who were treated with antipsychotics and had dopaminergic gene variant data.Results: Of 73 screened articles, 26 met the inclusion criteria. Among the gene variants studied, <i>COMT</i> rs4680 and <i>DRD2</i> rs1800497 showed consistent links to treatment responses, particularly in reducing symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores. The relationship between genetic variants and clinical outcomes was statistically significant (P=0.007), whereas the study design showed no such association (P=0.416). Forest plots revealed varied effect sizes across gene families, with <i>COMT</i> and <i>DRD2</i> generally showing odds ratios >1.0, indicating a favorable impact on treatment.Conclusion: Our findings suggest that certain dopaminergic gene variants, especially <i>COMT</i> rs4680 and <i>DRD2</i> rs1800497, may serve as valuable markers for predicting the response of patients with schizophrenia to antipsychotic therapy.

Precision and Future MedicineVol. 9(4)
Good health and well-being
Openalex Percentile: Top 31%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.